A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04590326 |
Recruitment Status :
Recruiting
First Posted : October 19, 2020
Last Update Posted : March 19, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is researching an investigational drug called REGN5668. Participants will receive additional investigational drugs in combination with REGN5668. These additional drugs include cemiplimab or REGN4018 (with or without sarilumab).
The main purposes of this study are to:
- Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
- Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus
This study has 2 parts. The purpose of Part 1 (Escalation) to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.
The study is looking at several other research questions, including:
- Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab or REGN4018
- How REGN5668 works in the body either alone and/or in combination with cemiplimab or REGN4018
- How much of the study drugs (REGN5668, cemiplimab, REGN4018) are in the blood
- To see if REGN5668 in combination with cemiplimab or REGN4018 works to treat cancer
- To find out how safe, tolerable, and effective in mitigating Cytokine Release Syndrome (CRS) sarilumab pretreatment is when given before REGN4018
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer Endometrial Cancer | Drug: REGN5668 Drug: Cemiplimab Drug: REGN4018 Drug: Sarilumab | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 612 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3) |
Actual Study Start Date : | December 9, 2020 |
Estimated Primary Completion Date : | April 27, 2027 |
Estimated Study Completion Date : | April 27, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Module 1
REGN5668 and cemiplimab
|
Drug: REGN5668
REGN5668 will be administered by once weekly intravenous (IV) infusion. Drug: Cemiplimab For Module 1, after a minimum of a 3-week monotherapy lead-in of REGN5668, cemiplimab will be administered concomitantly every 3 weeks (Q3W) by IV infusion.
Other Names:
|
Experimental: Module 2
REGN5668 and REGN4018
|
Drug: REGN5668
REGN5668 will be administered by once weekly intravenous (IV) infusion. Drug: REGN4018 For Module 2, a 4-5 week monotherapy lead-in of REGN4018 will be administered by once weekly IV infusion. After lead-in, REGN5668 and REGN4018 will be administered concomitantly. Drug: Sarilumab Administered by IV infusion as prophylaxis for mitigating potential CRS in patients receiving REGN4018 |
- Incidence of dose limiting toxicities (DLT) [ Time Frame: 42 days ]Dose escalation phase, Module 1
- Incidence of DLTs [ Time Frame: 21 days post combination administration ]Dose escalation phase, Module 2
- Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Through study completion, up to 5 years ]Primary: Dose escalation phase Secondary: Dose expansion phase
- Incidence of serious adverse events (SAEs) [ Time Frame: Through study completion, up to 5 years ]Primary: Dose escalation phase Secondary: Dose expansion phase
- Incidence of deaths [ Time Frame: Through study completion, up to 5 years ]Primary: Dose escalation phase Secondary: Dose expansion phase
- Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0]) [ Time Frame: Through study completion, up to 5 years ]Primary: Dose escalation phase Secondary: Dose expansion phase
- Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or REGN4018 [ Time Frame: Through study completion, up to 5 years ]Primary: Dose escalation phase Secondary: Dose expansion phase
- ORR defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) in combination with cemiplimab or REGN4018 (separately by cohort and combination) [ Time Frame: Through study completion, up to 5 years ]Primary: Dose expansion phase Secondary: Dose escalation phase
- Concentration of REGN4018 in serum over time [ Time Frame: Through study completion, up to 5 years ]Dose expansion phase
- Concentration of cemiplimab in serum over time [ Time Frame: Through study completion, up to 5 years ]Dose expansion phase
- ORR based on Immune-based therapy RECIST (iRECIST) [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- BOR based on RECIST 1.1 and iRECIST [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- DOR based on RECIST 1.1 and iRECIST [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- DCR based on RECIST 1.1 and iRECIST [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- PFS based on RECIST 1.1 and iRECIST [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- CA-125 change from baseline after treatment with REGN5668 in combinations with cemiplimab or REGN4018 (separately by cohort and combination) [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- Presence or absence of anti-drug antibodies against REGN5668 [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- Presence or absence of anti-drug antibodies against REGN4018 [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
- Presence or absence of anti-drug antibodies against cemiplimab [ Time Frame: Through study completion, up to 5 years ]Dose escalation and expansion phases
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
- Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
- Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
- Has adequate organ and bone marrow function as defined in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a life expectancy of at least 3 months
- Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol
Key Exclusion Criteria:
- Prior anti-cancer immunotherapy as defined in the protocol
- Recent treatment with anti-Programmed Cell Death (PD-1)/PDL-1 therapy
- Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
- Prior treatment with a MUC16-targeted therapy
- Expansion cohorts only: More than 4 prior lines of cytotoxic chemotherapy (including antibody drug conjugates)
- Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Has history of clinically significant cardiovascular disease as defined in the protocol
- Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).
Note: Other protocol-defined Inclusion/Exclusion criteria apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04590326
Contact: Clinical Trials Administrator | 844-734-6643 | clinicaltrials@regeneron.com |
United States, California | |
City of Hope | Recruiting |
Duarte, California, United States, 91010 | |
United States, Florida | |
H. Lee Moffitt Cancer Center | Recruiting |
Tampa, Florida, United States, 33612 | |
United States, Illinois | |
Northwestern Memorial Hospital | Recruiting |
Chicago, Illinois, United States, 60611 | |
University of Chicago | Recruiting |
Chicago, Illinois, United States, 60637 | |
United States, Massachusetts | |
Massachusetts General Hospital Cancer Center | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Dana Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
Karmanos Cancer Institute | Recruiting |
Detroit, Michigan, United States, 48201 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
United States, Ohio | |
The Ohio State University Wexner Medical Center | Recruiting |
Columbus, Ohio, United States, 43210 | |
United States, Washington | |
Seattle Cancer Care Alliance | Recruiting |
Seattle, Washington, United States, 98109 | |
Belgium | |
Universitair Ziekenhuis Leuven | Recruiting |
Leuven, Vlaams-Brabant, Belgium, 3000 |
Study Director: | Clinical Trial Management | Regeneron Pharmaceuticals |
Responsible Party: | Regeneron Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT04590326 |
Other Study ID Numbers: |
R5668-ONC-1938 2022-501904-83-00 ( Other Identifier: EUCT Number ) |
First Posted: | October 19, 2020 Key Record Dates |
Last Update Posted: | March 19, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy. |
Access Criteria: | Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf |
URL: | https://vivli.org/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Progressive Recurrent Refractory Serum CA-125 levels >= 2x ULN |
Endometrial Neoplasms Fallopian Tube Neoplasms Neoplasms by Site Neoplasms Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |
Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases Uterine Neoplasms Uterine Diseases Fallopian Tube Diseases Cemiplimab Antineoplastic Agents, Immunological Antineoplastic Agents |